BioSpace News Archive

Advisory - Health Canada safety review finds link between the use of Xeljanz and Xeljanz XR (tofacitinib) and increased risk of serious heart-related issues and cancer

Health Canada completed a safety review that confirmed a link between the use of Xeljanz/Xeljanz XR and the increased risks of serious heart-related problems and cancer, especially in older patients, patients who are current or past smokers, and patients with cardiovascular or cancer risk factors.

January 12, 2022
·
8 min read
BioMidwest

Amber Specialty Pharmacy and Hy-Vee Pharmacy Solutions Selected to Dispense TEZSPIRE™ (tezepelumab) for the Treatment of Severe Asthma

Amber Specialty Pharmacy and Hy-Vee Pharmacy Solutions announce today that they are now dispensing TEZSPIRE™ (tezepelumab), the first biologic to significantly reduce exacerbations in broad populations of patients with severe, uncontrolled asthma.

January 12, 2022
·
3 min read
Biotech Beach

Puma Biotechnology’s NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) for the treatment of breast cancer have been updated for 2022 and include two important changes involving neratinib (NERLYNX®).

January 12, 2022
·
7 min read
Adult and Pediatric Hemoconcentrators Market: Increase in prevalence of cardiac diseases to drive the market

Hemoconcentrators, also referred to as hemofilters or ultrafiltration devices, which contain a semipermeable membrane that allows passage of water and electrolytes out of the blood.

January 12, 2022
·
5 min read
Insulin Pens to Dominate the Global Insulin Delivery Devices Market Share

Fact.MR – A Market Research and Competitive Intelligence Provider: In 2020, the global market for insulin delivery devices is expected to reach US$ 14 billion.

January 12, 2022
·
6 min read
Infantile Spasms Therapeutics Market: Rising Prevalence of Infantile Spasms to Drive the Market

Infantile spasms therapeutics are used for the treatment of seizures or an epilepsy syndrome in young children, usually aged one year or below.

January 12, 2022
·
5 min read
Pediatric Cannulae Market: Rise in incidence of congenital heart defects among infants to drive the market

Cardiac surgery has experienced a tremendous growth in technological advancement, and the coronary bypass grafting has become routinely safe worldwide.

January 12, 2022
·
6 min read
Swine Influenza Market: High Prevalence of Infection and Development of Several Novel Drugs to Drive the Market

Swine influenza, also known as swine flu, is a highly contagious respiratory disease caused by Type-A influenza viruses that infect the respiratory tracts of pigs.

January 12, 2022
·
4 min read
Immuron Receives A$6.2 Million Award from U.S. DoD to Clinically Evaluate a Military Strength Dosing Regimen for Travelan

Immuron Limited, an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce the funding of a new research agreement with the U.S Department of Defense.

January 12, 2022
·
4 min read
Policy

CBMG Receives FDA Regenerative Medicine Advanced Therapy and Fast Track Designations for Bi-Specific Anti-CD19/CD20 CAR-T Cell Therapy for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Cellular Biomedicine Group Inc. announced that the Food and Drug Administration granted C-CAR039, a novel autologous bi-specific CAR-T therapy targeting both CD19 and CD20 antigens, both Regenerative Medicine Advanced Therapy Designation and Fast Track Designation for the treatment of patients with relapsed or refractory diffuse large B cell lymphoma.

January 12, 2022
·
4 min read